ARS Pharma's New CEO Refocuses on Providers and Profitability
Strategic pivot from DTC to targeted prescriber execution, with CSU expansion as the next growth driver.
SPRY · Earnings Call · 2026-08-13
A Change of Guard and a New Playbook
ARS Pharmaceuticals (SPRY) reported Q2 2026 earnings on August 13, with new CEO Donn Casale at the helm. In his inaugural call, Casale articulated a clear departure from the previous playbook, laying out three strategic prioritys: targeted provider commercial execution, financial discipline, and pipeline expansion into chronic spontaneous urticaria (CSU). This pivot comes after a period of heavy DTC spending under former CEO Richard Lowenthal, which drove brand awareness but not commensurate conversion. Casale noted, “Our primary objective is to increase market share, which we believe is the best indicator of commercial success for a product like neffy.” — Donn Casale, President and CEO · 2026-08-13 This shift is not just a tweak; it is a fundamental change in how ARS will allocate capital and measure success.
What I'm outlining is more than a shift in our commercial strategy. It is a fundamental change in how we manage our business and allocate capital.
From Broad DTC to Provider Conviction
The heart of the new strategy is a commercial strategy that moves away from broad direct-to-consumer advertising and toward high-frequency, provider-focused engagement. Management framed neffy as a prevention-based market, where patients and providers default to the status quo unless given a compelling reason to change. The new approach is already showing results: total U.S. market share doubled to 5% year-over-year, and within the field-targeted universe, share reached 8% versus 1% in non-targeted areas. As Casale explained in Q&A, “We'll certainly look at, obviously, the best indicator is scripts and market share, and that's going to be an important metric.” — Donn Casale, President and CEO · 2026-08-13 This focus on execution over broad awareness marks a stark contrast to the prior management's approach. Just two quarters ago, Lowenthal stated, “we expect that the direct-to-consumer spend in 2026 will be very similar to what we spent in 2025. It's about roughly $100 million between direct-to-consumer and direct-to-health care provider advertising.” — Richard Lowenthal, Co-Founder, President and CEO · 2026-03-09 Now, Casale is deliberately slashing that spend, citing more efficient channels like social and search.
Path to Breakeven and the CSU Catalyst
Financial discipline is a core pillar, with SG&A reduced by over 40% in the second half of 2026 compared to the first half, and a stated path to cash flow breakeven by the end of 2027. The company's revenue trajectory shows inflection, with total revenue growing from $2M in 2024Q4 to $23M in 2026Q1, though Q2 2026 dipped to $23M on a sequential basis. The gross margin of 62% in Q2 is expected to improve as manufacturing scales. Meanwhile, the CSU program represents a compelling upside. The Phase IIb readout has been pushed to Q1 2027 due to trial design requirements, but the market opportunity is significant—there are no approved on-demand treatments for CSU acute flares. As Casale noted, “Because we can leverage our existing commercial infrastructure and overlapping targeted prescribers, this program could represent a high-margin growth driver built entirely on top of our neffy foundation.” — Donn Casale, President and CEO · 2026-08-13 This is a long-term optionality play, but one that gets a clearer timeline with the readout shift.
The market has not been kind to SPRY, with the stock down 31.6% over the last 90 days and 47.8% from its recent peak. But the new CEO's focus on profitable execution and a disciplined cost structure could rebuild investor confidence. The question is whether this pivot can translate into sustained market share gains, especially as the company heads into the back-to-school season. In prior quarters, management relied on payer wins and DTC, but now the emphasis is on provider education and habit change. As Eric Karas said in May, “When we look at what they represent in terms of the number of covered lives, CVS is 15%, Anthem is 5% and Aetna is 4%.” — Eric Karas, Chief Commercial Officer · 2026-05-15 That payer progress is still foundational, but the new strategy adds a layer of urgency to convert coverage into prescriptions.
In summary, ARS is undergoing a necessary maturation from a launch phase to a sustainable commercial model. The combination of provider-focused execution, cost discipline, and the CSU pipeline gives a clearer picture of what the company will look like in 2027. Whether this is enough to reverse the stock's slide remains to be seen, but the direction is encouraging.